Developer of an eutectic ionic liquid designed to minimize the pervasive use of systemic drugs for the treatment of dermal diseases and symptoms. Cage Bio is based in San Carlos, CA. Its last reported valuation was $125 million in Jun 2019. It has raised $57.6 million across 3 recorded rounds; the latest was an $11 million early-stage round in Apr 2024.
Last reported valuation
$125.0M
Oct 2026
Priced at
—
Total raised
$57.6M
Last round
Early Stage VC
Apr 2024
Cap table — not yet on record
Cage Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Cage Bio with a free account
·Watch Cage Bio: the Monday email on marks, rounds and moves
